Immatics: PRAME Leader's Transition To Commercial Reality [Seeking Alpha]
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress [Yahoo! Finance]
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering Announcement [Yahoo! Finance]
Biotech Immatics to raise $125M through ordinary share offering [Seeking Alpha]